Navigation Links
US Cancer Pain Market to Reach $5 Billion by 2018 - Cancer Patient Growth Drives Value
Date:2/3/2009

inical trials for the treatment of cancer pain, but more than 150 agents could have the potential to treat cancer pain. All of these agents are reviewed in this report. Currently, worldwide, 42 drugs with the potential to treat cancer pain have reached Phase III+ in their clinical development. The 15 Phase III+ compounds that are being studied specifically for the treatment of cancer pain include novel delivery approaches for the opioid receptor agonist fentanyl (nine compounds), novel formulations of morphine (two compounds), an NMDA receptor antagonist (intranasal ketamine), a topical combination of ketamine and amitriptyline (NP-1, for chemotherapy-induced neuropathy), an IM sodium channel antagonist (tetrodotoxin), and an oral serotonin receptor agonist that stimulates nerve growth factor release (xaliproden).

Most of the drugs recently approved in the world for the treatment of cancer pain are opiates. One exception is GW's dronabinol/cannabidiol (Sativex), a cannabinoid receptor agonist recently approved in Canada for the treatment of cancer pain. The US has not seen a recent approval, but BDSI's ONSOLIS has reached a pre-registration stage of development in the US.

ADDITIONAL SERVICES AND REPORTS BY WWMR, INC. INCLUDE:

  • US Pain Clinic Monitor (available now)
  • 2008 US Neuropathic Pain (available now)
  • 2008 US Back Pain (coming soon)

WWMR, Inc. is a leader in pain reporting, and also designs and executes research which brings clarity, reveals innovative opportunities and provides deeper understanding across many therapy areas and all phases of drug development. This enables our clients to:

  • Demonstrate the commercial value of product/partnering opportunities
  • Optimize the revenue potential of their product portfolio
  • Identify and
    '/>"/>

SOURCE WWMR, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Prayers From Maria - Childrens Glioma Cancer Foundation Hosts Sunflower Soiree
2. NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines
3. Polymedco Introduces New Colorectal Cancer Educational Website
4. Stool-Based Colon Cancer Tests Vary Widely in Accuracy
5. UCLA scientists develop crystal ball for personalized cancer treatment
6. Workforce shortages in mammography could threaten early detection rates for breast cancer
7. Inflammation in colon may get doused before fueling cancer development
8. New Clues to Stopping Colitis-Linked Cancer
9. 2 immune-system proteins linked to colitis-associated cancer
10. PET/CT may improve prognosis for patients with inflammatory breast cancer
11. Top Belgian Cancer Center Becomes First in Country to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Cytovance® Biologics, ... biopharmaceutical contract development manufacturing company (CDMO), announced today that it has entered into ... in cash. , The addition of Cytovance Biologics to Hepalink USA ...
(Date:8/27/2015)... ... 27, 2015 , ... Susan Harris and the team at LifeStream ... to pre- and post-menopause, chemotherapy, and child birth. , The MonaLisa Touch ... to the vaginal tissue, revitalizing cells so they make more collagen, an essential component ...
(Date:8/27/2015)... Rocky Hill, CT (PRWEB) , ... August 27, 2015 , ... ... Portal Companies List. , “The companies selected have the platforms required not only to ... training,” said Ken Taylor, President of Training Industry, Inc. , For six consecutive ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... firm that helps libraries, publishers and companies leverage key operational, technical, business ... the VIVO Project. Gunter Media Group, Inc., will provide VIVO related services ...
(Date:8/27/2015)... Newport Beach, CA (PRWEB) , ... August 27, ... ... services and products, announced today that the new issue of Chairside® magazine, its ... the latest issue, Volume 10, Issue 3, as well as past issues of ...
Breaking Medicine News(10 mins):Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 2Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 3Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 2Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 3
... , , BATESVILLE, Ind., and ... today announced a strategic partnership agreement to integrate the Radianse ... system. With this move, Hill-Rom intends to extend its ... financial and technical obstacles for health care customers as they ...
... NOVATO, Calif., Sept. 2 BioMarin Pharmaceutical Inc. (Nasdaq: ... Chief Financial Officer of BioMarin, will present a company update at the ... at 4:25 p.m. ET. , , Interested ... the investor section of the BioMarin website, www.BMRN.com . ...
... SOMERSET, N.J., Sept. 2 Meda Pharmaceuticals ... (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for ... rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% ... for patients who suffer from seasonal allergies. ASTEPRO Nasal Spray ...
... /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin Board: RNER; "the Company") announced ... publicized the creation of "Opinions of the,CPC Central Committee and ... Health Care System" ("Opinion"). , The ... a,doctor more easily. Reduced cost is the short-term goal and ...
... , , , , ... Mass., Sept. 2 /PRNewswire-FirstCall/ -- ... company that is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and ... Bob Doman, President and Chief Executive Officer, will present a corporate ...
... , , , ... , a medical device company, today announced that its ... the U.S. Food and Drug Administration (FDA) for the direct delivery ... may be in the treatment of cancer. , , ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:BioMarin to Present at the Thomas Weisel Partners Healthcare Conference 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 4Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 5Health News:RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis 2Health News:RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis 3Health News:DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 4
(Date:8/27/2015)... 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first patient ... the United States in a trial assessing ... for blockages in the main artery of the leg. The ... potentially less risk for stent fracture or re-narrowing after the ... multicenter clinical trial of the BioMimics 3D Stent System and ...
(Date:8/27/2015)... YORK , August 27, 2015 ... published by Persistence Market Research titled "Global Market ... Witness Highest Growth by 2021", the urinary catheters market is ... the end of 2015. It is anticipated to ... 2021, to reach US$1,755.0 Mn by 2021. ...
(Date:8/27/2015)... 2015  QB3@953—a San Francisco ... California (UC) research institute and biotech accelerator— today ... identify and facilitate collaborations to translate early drug ... The agreement formalizes a relationship between QB3@953 ... and creates a new channel for DPAc to ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... Berger Health System, recognized as one of the ... to AutoCarousel® HD by Talyst, a leader of pharmacy ... has a built-to-last 10 years guarantee. Berger ... is also implementing AutoPharm®, AutoPack™ and AutoLabel® to help ...
... Lineagen, Inc., an innovative molecular diagnostics company focused on ... nonprofit subsidiary of the National Multiple Sclerosis Society, today ... validation of a blood-based assay for multiple sclerosis (MS). ... test that can aid clinicians in diagnosing MS, distinguishing ...
Cached Medicine Technology:Berger Health System Partners With Pharmacy Automation Leader to Improve Patient Safety 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 3Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 4
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Medicine Products: